Companies and AI developments
Updates
Daily market commentary, company analyses, investment stories and AI news. Price-only updates require a cumulative move of greater than 15% from the last published assessment. Newest first.
Q3 2026 earnings Inter & Co increased net income by 26% to BRL 425 million and CET1 to 12.2%, supporting a stronger business assessment. Late delinquency rose to 5.3%, and the higher reference price lowered attractiveness with unchanged scenarios.
Published a new analysis of Blue Owl Capital (OWL).
Meta completed a USD 15 billion bond issue and added 6 million Class A shares to forward agreements. The financing adds capacity to invest along with interest costs and potential dilution; company strength remains 7.4/10.
Five more states joined the FTC suit against Hims & Hers, and the filing on a board appointment disclosed separate paid agreements. Legal and governance scrutiny increased; the new evidence does not change company strength of 5.1/10 or price attractiveness of 4.4/10.
Q3 2026 earnings Q3 showed four new revenue-generating sites and better terms on new contracts, but delays and planned 2027 capex of USD 40–45 billion leave company strength at 6.6/10. The lower USD 115.88 close lifts attractiveness to 6.3/10 even as higher capital requirements reduce both modeled terminal prices.
After the first period of the Delivery Hero offer, 66.56% of shares and votes were attributed to the bidder, reducing acceptance risk. Settlement and synergies remain uncertain; company strength and price attractiveness are unchanged.
STRL closed at USD 292.39, 15.7% above the previous assessment price, reducing the cushion against permitting risk. Price attractiveness falls from 7.7 to 6.8/10; company strength remains 7.8/10 because the new Texas information does not establish an impact on specific contracts.
Grab signed Malaysian AI infrastructure agreements with a proposed initial contribution of USD 750 million and returns yet to be demonstrated. Allowing for the potential capital burden lowers company strength to 6.7/10 and price attractiveness to 4.9/10 despite a lower entry price.
Q3 2026 earnings Revenue grew 32%, adjusted EBITDA margin reached 19% and higher FY2026 guidance confirms operating leverage. Business strength rises to 6.8/10; at USD 32.85 attractiveness remains 3.0/10.
The Q3 call and filed 10-Q refine the recovery path: commercial cost trend remains above 11%, Medicaid margins are negative and OptumHealth’s 6–8% margin target extends to 2028. Company strength remains 7.2/10; the higher USD 405.40 entry price lowers attractiveness to 5.5/10.
MFIC results sharpened the acquired portfolio's risk: NAV fell to USD 12.86, leverage was 1.43×, and nonaccruals remain elevated. ARCC strength stays 7.3/10; the higher price reduces attractiveness to 6.2/10.
The Q3 10-Q confirmed repayment of the remaining USD 428 million in cash without issuing shares and added SoFiUSD data. Scores and scenarios remain unchanged.
Jensen Huang’s departure and Colette Kress’s interim appointment increase execution uncertainty and reduce business strength to 7.8/10. The lower USD 164.54 quote raises price attractiveness to 6.2/10 despite lower terminal prices in both scenarios.
ZETA rose 16.4% from the prior assessment to a $37.74 close, reducing the modeled base three-year return to 9.9% and price attractiveness to 3.5/10. Business strength remains 6.9/10; no new operating evidence was added.
The added Form 10-Q showed that loans 91–360 days past due were about 19.3% of the reported portfolio; the disclosure sharpens risk evidence but does not change business strength. At the $1,490.26 close, price attractiveness rises to 5.5/10.
Q3 2026 earnings Base44 approached $250 million of ARR, reached a 58% gross margin, and its first annual cohort renewed above management expectations. Lower nine-month FCF and reduced FCF-margin guidance limit the improvement in the assessment.
Q3 2026 earnings Revenue rose 49%, but subscribers declined sequentially, gross margin fell to 57%, and full-year adjusted EBITDA guidance was reduced. The $19.13 price also raises the modeled base three-year return to about 61%, while downside risk remains substantial.
Q3 2026 earnings Growth excluding Marigold and political campaigns reached 30%, while customer KPIs, margins and FCF accelerated and management raised guidance. Business strength rose to 6.9/10; at the USD 32.42 close, price attractiveness is 4.2/10.
The $25 billion bond issuance confirms Microsoft's access to capital but adds interest claims, while Northern Trust demonstrates real agent use without disclosing the economics for Microsoft. Strength remains 8.4/10, and the higher $545.18 close reduces attractiveness to 5.9/10.
A new euro bond issuance and the Wyoming data-center plan confirm another capital-intensive expansion step and increase the importance of future cash returns; without new operating evidence, strength remains 7.8/10. Attractiveness remains 4.5/10 at the $283.93 close.